Imagine your immune system is like a security team that forgets the intruder's face too quickly. This work creates better 'training manuals' using four different delivery methods to help the body remember the virus for much longer. It's like upgrading from a temporary sticky note to a permanent guidebook so you don't need constant boosters.
Current COVID-19 vaccines suffer from waning immunity and are frequently bypassed by new viral variants. This creates a constant need for boosters and reduces the long-term effectiveness of public health strategies.
Four vaccine candidates (DC-targeting, nanoparticles, MVA, and mRNA) and a secure LabKey-based data warehouse for clinical and experimental datasets.
If you are a vaccine manufacturer dealing with waning immunity and new variants — this project developed four vaccine platforms (DC-targeting, nanoparticles, MVA, and mRNA) that elicit more durable immune responses. This allows for the creation of products that require fewer booster shots.
If you are a drug delivery specialist dealing with inefficient antigen targeting — this project developed a CD40 DC-targeting method and nanoparticle platforms. These tools improve how the body recognizes and reacts to viral proteins.
If you are a strategy firm dealing with low vaccination rates — this project developed research on the determinants of population adherence. This provides data to improve the implementation of vaccination campaigns.
Based on available project data, the specific unit cost or pricing for the vaccine candidates is not provided; only the total EU contribution of EUR 8,972,900 is listed.
The project has produced GMP clinical lots for the CD40 DC-targeting and MVA vaccines, which is a prerequisite for industrial scaling, though full-scale manufacturing data is not detailed.
Based on available project data, specific licensing terms are not mentioned, but the project involves 2 industry partners who typically manage commercialization rights.
The project period runs from 2024-01-01 to 2028-12-31, with an Experimental Medicine Trial (EMT) currently underway in three European clinical centres.
The project includes a specific pillar to investigate population adherence and acceptability to ensure the next generation of vaccines can be effectively implemented in preparedness tracks.
The consortium is heavily research-driven, featuring 11 partners across 5 countries. While it is dominated by universities (5) and research institutes (3), it maintains an 18% industry ratio with 2 industrial partners. This structure suggests a transition from academic discovery to clinical validation, supported by a significant EU investment of nearly 9 million euros.
Contact the Institut National de la Santé et de la Recherche Médicale (INSERM) in France.
Contact us to explore licensing opportunities for the four vaccine platforms.
